Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)167.00m
- Net income in EUR622.00k
- Incorporated1986
- Employees509.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc | 58.27m | -165.34m | 1.30bn | 267.00 | -- | 3.91 | -- | 22.28 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Nanjing Vazyme Biotech Co Ltd | 183.58m | 3.09m | 1.32bn | 2.70k | 409.23 | 2.53 | -- | 7.18 | 0.0615 | 0.0615 | 3.84 | 9.97 | 0.2644 | 1.06 | 3.57 | 519,483.10 | 0.4122 | 13.16 | 0.5237 | 15.92 | 70.21 | 70.50 | 1.56 | 23.92 | 4.17 | -- | 0.1436 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Fagron NV | 820.76m | 77.94m | 1.33bn | 3.46k | 17.09 | 2.80 | 11.40 | 1.62 | 1.06 | 1.06 | 11.20 | 6.48 | 0.7931 | 3.53 | 10.03 | 237,214.50 | 7.58 | 7.63 | 9.45 | 9.77 | 44.17 | 43.49 | 9.55 | 10.23 | 1.08 | 4.67 | 0.438 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Chongqing Genrix Biophrmctcl Co Ltd | 1.77m | -102.02m | 1.34bn | 547.00 | -- | 4.36 | -- | 757.41 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Shanghai Henlius Biotech Inc | 738.99m | 90.71m | 1.35bn | 3.55k | 14.89 | 3.99 | 9.69 | 1.82 | 1.37 | 1.37 | 11.11 | 5.10 | 0.5764 | 1.90 | 6.82 | 1,667,562.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 7.60 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| Biotest AG | 707.00m | 68.50m | 1.36bn | 2.46k | 24.20 | 3.11 | -- | 1.93 | 1.71 | 1.71 | 18.04 | 13.33 | 0.5244 | 1.08 | 3.33 | 291,426.20 | 5.08 | -0.0693 | 6.03 | -0.079 | 33.95 | 28.43 | 9.69 | -0.1527 | 0.7828 | 2.59 | 0.5379 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 1.25bn | -4.58m | 1.36bn | 8.06k | -- | 1.26 | -- | 1.09 | -0.0412 | -0.0412 | 8.20 | 6.83 | 0.555 | 3.23 | 4.28 | 1,184,162.00 | -0.3467 | 1.95 | -0.5663 | 3.77 | 39.08 | 40.58 | -0.6248 | 3.43 | 0.6491 | -- | 0.3696 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Pharma Mar SA | 167.00m | 622.00k | 1.37bn | 509.00 | 1,961.84 | 7.18 | 201.08 | 8.19 | 0.038 | 0.038 | 9.50 | 10.39 | 0.4894 | 0.2255 | 5.23 | 328,100.20 | 0.1823 | 18.52 | 0.2456 | 25.89 | 94.42 | 93.76 | 0.3725 | 28.87 | 2.13 | -7.53 | 0.2256 | -- | -19.45 | 7.77 | -97.70 | -- | 46.37 | -- |
| China Traditional Chinese Med Hldg CoLtd | 2.25bn | 120.20m | 1.41bn | 17.72k | 11.69 | 0.5019 | 5.13 | 0.6234 | 0.1959 | 0.1959 | 3.67 | 4.56 | 0.453 | 1.54 | 1.82 | 1,069,108.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 7.39 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| SSY Group Ltd | 788.20m | 166.41m | 1.41bn | 5.80k | 8.51 | 1.60 | 6.32 | 1.79 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Harrow Inc | 160.41m | -31.68m | 1.43bn | 315.00 | -- | 26.07 | -- | 8.90 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 455.79m | 63.14m | 1.44bn | 2.88k | 22.78 | 2.75 | -- | 3.16 | 1.12 | 1.12 | 8.08 | 9.28 | 0.6872 | 6.42 | 8.53 | 1,208,299.00 | 9.74 | 10.82 | 11.64 | 13.47 | 44.84 | 41.18 | 14.17 | 14.08 | 4.40 | -- | 0.0936 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Strides Pharma Science Ltd | 495.80m | 19.90m | 1.44bn | 3.07k | 72.44 | 5.63 | 34.44 | 2.90 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Data as of Nov 21 2024. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR
7.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 445.23k | 2.40% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 198.34k | 1.07% |
| RWC Asset Management LLPas of 08 Mar 2023 | 196.41k | 1.06% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 125.66k | 0.68% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 109.67k | 0.59% |
| Jupiter Asset Management Ltd.as of 31 Jul 2024 | 61.13k | 0.33% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 59.00k | 0.32% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 54.42k | 0.29% |
| DWS Investments (UK) Ltd.as of 07 Nov 2024 | 28.90k | 0.16% |
| Caixabank Asset Management SGIIC SAas of 30 Jun 2024 | 27.04k | 0.15% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
